Gtb biopharma
WebApr 12, 2024 · About GT Biopharma (OTCMKTS:GTBP) Stock GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of the immuno-oncology therapeutic products based proprietary TriKE NK cell engager platform. WebSep 22, 2024 · BEVERLY HILLS, CA / ACCESSWIRE / September 22, 2024 / GT Biopharma, Inc. (OTCQB:GTBP)(GTBP.PA) an immuno-oncology company focused on innovative therapies based on the Company's proprietary NK cell engager (TriKE™) technology announced today it completed treatment of the first patient enrolled at Dose …
Gtb biopharma
Did you know?
WebJun 23, 2024 · About GT Biopharma, Inc. GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of … WebSep 20, 2024 · GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on our proprietary TriKE ® NK cell...
WebMar 17, 2024 · GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based our proprietary TriKE™ NK cell engager platform. WebMar 30, 2024 · GT Biopharma Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update Proforma cash of approximately $23.0 million includes $16.5 million in cash as of December 31, 2024, plus $6.5 million in gross proceeds received from a registered direct offering priced at a premium to market on January 4, 2024.
WebGT Biopharma advanced its trispecific natural killer (NK) cell engager GTB-3550 into a phase I/II trial earlier this year, for high- risk haematological malignancies. Innate Pharma is working on trispecific NK cell engagers for cancer settings. Companies including Numab Therapeutics have presented preclinical data WebNov 12, 2024 · TAMPA, FL / ACCESSWIRE / November 12, 2024 / GT Biopharma, Inc. (OTCQB:GTBP) (GTBP.PA) an immuno-oncology company focused on innovative therapies based on the Company's proprietary NK cell engager (TriKE™) technology is pleased to announce its abstract "GTB-3550 TriKE™ for the Treatment of High-Risk …
WebSep 15, 2024 · GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on our proprietary TriKE ® NK cell...
WebSep 13, 2024 · GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products … inbound url request with crafted stringsWebAug 13, 2024 · GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on our proprietary TriKE ® NK cell... inbound usa insurance reviewWebSep 13, 2024 · GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on our proprietary TriKE ® NK cell... in and out south tweedWebSep 22, 2024 · Mr. Anthony Cataldo, the Chairman and Chief Executive Officer of GT Biopharma commented "we are pleased to see a reduction in AML blast levels at a dose of 25mcg/kg/day of GTB-3550." inbound unloadWebAug 3, 2024 · GT Biopharma's lead TriKE™ product candidate, GTB-3550 TriKE™, is being evaluated in a multicenter Phase I/II trial (ClinicalTrials.gov NCT03214666) for the treatment of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and other CD33+ hematopoietic malignancies. inbound usmcWebBEVERLY HILLS, Calif., April 12, 2024 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative … inbound utilizationWebFeb 26, 2024 · Mr. Anthony Cataldo, the Chairman and Chief Executive Officer of GT Biopharma commented "we are pleased to have dosed the first patient in our GTB-3550 clinical trial, and thank our investors for ... inbound ups